NO3175985T3 - - Google Patents

Info

Publication number
NO3175985T3
NO3175985T3 NO16202228A NO16202228A NO3175985T3 NO 3175985 T3 NO3175985 T3 NO 3175985T3 NO 16202228 A NO16202228 A NO 16202228A NO 16202228 A NO16202228 A NO 16202228A NO 3175985 T3 NO3175985 T3 NO 3175985T3
Authority
NO
Norway
Application number
NO16202228A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3175985T3 publication Critical patent/NO3175985T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
NO16202228A 2011-07-01 2012-05-31 NO3175985T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503980P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
NO3175985T3 true NO3175985T3 (de) 2018-04-28

Family

ID=46513864

Family Applications (1)

Application Number Title Priority Date Filing Date
NO16202228A NO3175985T3 (de) 2011-07-01 2012-05-31

Country Status (21)

Country Link
US (2) US8962610B2 (de)
EP (2) EP2966067B1 (de)
JP (3) JP6470969B2 (de)
KR (1) KR101919634B1 (de)
CN (2) CN103635467B (de)
AR (1) AR086829A1 (de)
AU (1) AU2012279214B2 (de)
BR (1) BR112013032027A2 (de)
CA (1) CA2838234A1 (de)
EA (2) EA025095B1 (de)
ES (2) ES2657169T3 (de)
HK (2) HK1197061A1 (de)
IL (1) IL229714B (de)
MA (1) MA35808B1 (de)
MX (1) MX338916B (de)
NO (1) NO3175985T3 (de)
PL (2) PL2726469T3 (de)
PT (2) PT2966067T (de)
SI (2) SI2966067T1 (de)
TW (1) TWI466873B (de)
WO (1) WO2013006463A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276537B2 (en) 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EP2588197B1 (de) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Kondensierte heterozyklische verbindungen als ionenkanalmodulatoren
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (de) 2011-07-01 2018-04-28
WO2013112932A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
AU2014230812B2 (en) * 2013-03-13 2016-04-07 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
EP3567045B1 (de) 2015-07-02 2022-01-12 F. Hoffmann-La Roche AG Benzoxazepin-oxazolidinon-verbindungen und verfahren zur verwendung
US10065970B2 (en) 2015-09-08 2018-09-04 Genentech, Inc. Tricyclic PI3K inhibitor compounds and methods of use
CN106046021A (zh) * 2016-05-26 2016-10-26 天津药物研究院有限公司 一类含溴的噻吩并吡啶类衍生物及其制备方法和用途
WO2018048977A1 (en) 2016-09-08 2018-03-15 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxazepin compounds
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
JP7105797B2 (ja) 2016-11-28 2022-07-25 プラクシス プレシジョン メディシンズ， インコーポレイテッド 化合物及びその使用方法
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN108084187A (zh) * 2017-12-15 2018-05-29 宜昌人福药业有限责任公司 苯并二氮杂*类氢化物
TWI831786B (zh) 2018-05-30 2024-02-11 美商普雷西斯精密藥品公司 離子通道調節劑
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
WO2023174374A1 (zh) * 2022-03-16 2023-09-21 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2867616A (en) 1950-05-17 1959-01-06 Syntex Sa 7-dehydro diosgenin compounds and process for making same
US2867618A (en) 1957-02-14 1959-01-06 Dow Chemical Co 3, 4-dihydro-2h-1, 3-benzoxazine
US2826575A (en) 1957-05-06 1958-03-11 Dow Chemical Co 3, 3'-alkylenebis
NL128591C (de) 1965-07-02
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
CH482404A (de) 1967-12-14 1969-08-15 Ciba Geigy Verwendung von Arylguanaminen zum antimikrobiellen Ausrüsten bzw. zum Schützen von Textilfasern gegen Mikroorganismen
US3594372A (en) 1968-08-13 1971-07-20 American Home Prod Pyrimido(4,5-e)(1,4)oxazepin-5-ones and derivatives thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4230705A (en) 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4244953A (en) 1979-10-24 1981-01-13 American Cyanamid Company Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4812565A (en) 1982-09-30 1989-03-14 A. H. Robins Company, Incorporated Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4654343A (en) 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4746655A (en) 1987-06-10 1988-05-24 A. H. Robins Company, Incorporated Fused aromatic-spiropiperidine oxazepinones(and thiones)
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE4010488A1 (de) 1990-03-31 1991-10-02 Hoechst Ag Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
CN1060467A (zh) 1990-09-25 1992-04-22 武田药品工业株式会社 1，3-苯并嗪衍生物、其生产方法和用途
JPH04209692A (ja) 1990-12-03 1992-07-31 Asahi Glass Co Ltd フォトクロミック材料
ATE152102T1 (de) 1991-05-10 1997-05-15 Takeda Chemical Industries Ltd Pyridinderivate, deren herstellung und anwendung
AU666318B2 (en) 1991-06-28 1996-02-08 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5939412A (en) 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5674863A (en) 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH061779A (ja) 1992-02-06 1994-01-11 Wakamoto Pharmaceut Co Ltd ベンズオキサジノン誘導体
JPH06107647A (ja) 1992-08-12 1994-04-19 Takeda Chem Ind Ltd １，３−ベンゾオキサジン誘導体の製造法
US6011150A (en) 1992-11-13 2000-01-04 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US5442055A (en) 1992-11-13 1995-08-15 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
GB9225860D0 (en) 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9226302D0 (en) 1992-12-17 1993-02-10 Smithkline Beecham Plc Pharmaceuticals
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
DE19526173A1 (de) 1995-07-18 1997-01-30 Hoechst Ag Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung
JPH09157262A (ja) 1995-12-08 1997-06-17 Tanabe Seiyaku Co Ltd アゼチジノン誘導体及びその合成中間体の製法
US5773186A (en) 1996-02-19 1998-06-30 Fuji Photo Film Co., Ltd. Heat-sensitive recording material
WO1998004542A1 (en) 1996-07-26 1998-02-05 Nissan Chemical Industries, Ltd. Chroman derivatives
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
GB9619492D0 (en) 1996-09-18 1996-10-30 Smithkline Beecham Plc Novel treatment
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
DE19716237A1 (de) 1997-04-18 1998-10-22 Basf Ag Substituierte Benzyloxyimino-Verbindungen
JP2001526643A (ja) 1997-04-18 2001-12-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
US6417362B1 (en) 1997-05-30 2002-07-09 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
JP3964053B2 (ja) 1997-07-10 2007-08-22 三井化学株式会社 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法
ES2165193T3 (es) 1997-09-08 2002-03-01 Unilever Nv Metodo para aumentar la actividad de una enzima.
CA2315763A1 (en) 1998-01-21 1999-07-29 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
EP1054877A1 (de) 1998-02-11 2000-11-29 Du Pont Pharmaceuticals Company Cyclische sulfonamid-derivate als metallprotease-inhibitoren
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
EP1082315A1 (de) 1998-06-05 2001-03-14 Icagen, Inc. Kalium-kanal-inhibitoren
AU755855B2 (en) 1998-06-16 2002-12-19 Merck Sharp & Dohme Limited Triazolo-pyridine derivatives as ligands for GABA receptors
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
KR20020005662A (ko) 1999-04-09 2002-01-17 기따자또 이찌로 질소함유 복소환화합물 및 벤즈아미드화합물 및 그 것을함유해서 되는 의약
CA2373073A1 (en) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6121916A (en) 1999-07-16 2000-09-19 Eaton-Vorad Technologies, L.L.C. Method and apparatus for recognizing stationary objects with a moving side-looking radar
BR0014153A (pt) 1999-08-27 2002-05-07 Procter & Gamble Componentes de intensificação de branqueamento, composições e métodos de lavagem
BR0013610A (pt) 1999-08-27 2002-07-16 Procter & Gamble Componentes de formulções de ação rápida,composições e métodos para lavar roupa empregando os mesmos
CA2381903A1 (en) 1999-08-27 2001-03-08 The Procter & Gamble Company Color safe laundry methods employing cationic formulation components
AU6935800A (en) 1999-08-27 2001-03-26 Procter & Gamble Company, The Controlled availability of formulation components, compositions and laundry methods employing same
ATE311432T1 (de) 1999-08-27 2005-12-15 Procter & Gamble Stabile substanzen, zusammensetzungen und waschverfahren zu deren verwendung
CZ2002687A3 (cs) 1999-08-27 2002-09-11 The Procter & Gamble Company Barvu zachovávající prací způsoby používající formulační složky s obojetnými ionty
CN1384867A (zh) 1999-08-27 2002-12-11 宝洁公司 稳定性提高的配制组分、使用该组分的组合物和洗衣方法
CZ2002802A3 (cs) 1999-09-17 2003-02-12 Nissan Chemical Industries, Ltd. Benzopyranové deriváty
AU7319800A (en) 1999-09-24 2001-04-24 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
EP1218367A1 (de) 1999-10-05 2002-07-03 Nissan Chemical Industries, Ltd. 4-oxobenzopyranderivate
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU781365B2 (en) 1999-12-21 2005-05-19 Icagen, Inc. Potassium channel inhibitors
JP2003533525A (ja) 2000-05-15 2003-11-11 ダーウィン・ディスカバリー・リミテッド Ｍｍｐおよびｔｎｆ阻害活性を有するヒドロキサム酸およびカルボン酸誘導体
US6956033B2 (en) 2000-08-01 2005-10-18 Ono Pharmaceutical Co., Ltd. 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient
US20040058915A1 (en) 2000-08-29 2004-03-25 Khanna Ish Kumar Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
AU1296902A (en) 2000-09-20 2002-04-02 Merck & Co Inc Isoquinolinone potassium channel inhibitors
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002051441A1 (fr) 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
ATE323701T1 (de) 2001-03-09 2006-05-15 Pfizer Prod Inc Triazolopyridine als entzündungshemmende mittel
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
SK15782003A3 (sk) 2001-06-25 2004-05-04 Nissan Chemical Industries, Ltd. Substituované benzopyránové deriváty proti arytmiám
JP2005089298A (ja) 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
ATE374183T1 (de) 2001-11-13 2007-10-15 Schering Corp Nk1-antagonisten
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2003277384A (ja) 2002-03-26 2003-10-02 Kyorin Pharmaceut Co Ltd 縮合ニ環式ピリジン誘導体
JP2003321461A (ja) 2002-04-25 2003-11-11 Kyorin Pharmaceut Co Ltd 縮合ビフェニル誘導体
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
AU2003262073A1 (en) 2002-09-20 2004-04-08 Tsumura And Co. Antitussives
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AU2003285946A1 (en) 2002-10-22 2004-05-13 The Trustees Of The University Of Pennsylvania Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
AU2003290577B2 (en) 2002-11-07 2008-12-11 Merck Sharp & Dohme Corp. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN100430386C (zh) 2002-11-07 2008-11-05 默克公司 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
KR20050094840A (ko) 2003-01-13 2005-09-28 코텍스 파마슈티칼스, 인크. 수면 부족 및 스트레스로 인한 인식 저하의 치료방법
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
DE10317526A1 (de) 2003-04-16 2004-11-04 Degussa Ag Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen
AU2004232939A1 (en) 2003-04-17 2004-11-04 Merck Sharp & Dohme Corp. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
WO2004096767A1 (en) 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
WO2004101509A2 (en) 2003-05-06 2004-11-25 Case Western Reserve University Functionalized benzoxazines, polymers and copolymers thereof
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
SI1641803T1 (sl) 2003-06-11 2009-08-31 Xention Ltd Tienopirimidinski derivati kot inhibitorji kalijevih kanalov
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US20060148805A1 (en) 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
AU2004260624A1 (en) 2003-07-21 2005-02-10 Solvay Pharmaceuticals Gmbh Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
CN1894222A (zh) 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
DE10348298A1 (de) 2003-10-17 2005-05-19 Solvay Pharmaceuticals Gmbh Amidomethyl-substituierte 2-(4-Sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-ylderivade, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
TW200514582A (en) 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
CA2550064A1 (en) 2003-12-18 2005-07-07 Pfizer Products Inc. Methods of treating acute inflammation in animals with p38 map kinase inhibitors
ES2526614T3 (es) 2004-03-05 2015-01-13 Nissan Chemical Industries, Ltd. Compuesto de benzamida sustituida con isoxazolina y agente de control de organismos nocivos
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2005121149A1 (en) 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
WO2006002470A1 (en) 2004-06-30 2006-01-12 Monash University Chiral ligands for asymmetric catalysis
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
CA2577060A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
CA2576465A1 (en) 2004-08-23 2006-03-02 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2579850A1 (en) 2004-09-13 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirohydantoin cgrp receptor antagonists
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
CA2498969A1 (en) 2004-11-01 2006-05-01 Institut De Cardiologie De Montreal Acetylcholine-dependent current as a novel ionic target for atrial fibrillation
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
JP2006203875A (ja) 2004-12-24 2006-08-03 Matsushita Electric Ind Co Ltd 受信装置
WO2006091897A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
KR100609101B1 (ko) 2005-03-11 2006-08-08 주식회사 신화성물산 물수건 공급장치의 물 분사노즐 및 그 제조방법
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
US7714150B2 (en) 2005-04-12 2010-05-11 Solvay Pharmaceuticals Gmbh Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives
AU2006234295B2 (en) 2005-04-12 2011-10-13 Solvay Pharmaceuticals Gmbh Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers
US20080176830A1 (en) 2005-04-14 2008-07-24 Adams Nicholas D Compounds, Compositions, and Methods
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
JP2008543867A (ja) 2005-06-17 2008-12-04 ワイス セロトニン阻害剤ならびに５−ｈｔ１ａアゴニストおよびアンタゴニストとして有用な三環系化合物
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
WO2007004028A2 (en) 2005-06-30 2007-01-11 Ranbaxy Laboratories Limited Processes for the preparation of penems and its intermediate
WO2007004960A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer’s desease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson’s disease
GB0516963D0 (en) 2005-08-18 2005-09-28 Carbonite Corp Liquid dispensers
US8932641B2 (en) 2005-08-26 2015-01-13 Amnos Co., Ltd. Dried amnion and method for drying treatment of amnion
EP1931652A2 (de) 2005-09-21 2008-06-18 Incyte Corporation Amidverbindungen und ihre verwendung als arzneimittel
WO2007038209A2 (en) 2005-09-23 2007-04-05 Schering Corporation Fused tetracyclic mglur1 antagonists as therapeutic agents
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
US8071772B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirolactam bicyclic CGRP receptor antagonists
EP1954135B1 (de) 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Spirolactam-aryl cgrp-rezeptor-antagonisten
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
KR20080082618A (ko) 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Ａｌｋ5 조절제를 사용한 안압의 조절
US8013073B2 (en) 2005-12-30 2011-09-06 Chevron Oronite Company Llc Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
KR20080104351A (ko) 2006-03-31 2008-12-02 노파르티스 아게 유기 화합물
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
AU2007258313A1 (en) 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
WO2008005338A1 (en) 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
WO2008007661A1 (fr) 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Composé hétérocyclique tricycique et son utilisation
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CN101528691B (zh) 2006-08-22 2014-11-26 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
JP2010505855A (ja) 2006-10-06 2010-02-25 アボット・ラボラトリーズ 新規なイミダゾチアゾール類およびイミダゾオキサゾール類
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
CL2007003108A1 (es) 2006-10-28 2008-07-18 Methylgene Inc Envivo Pharmace Compuestos derivados de n-hidroxiamida sustituida con heterociclos, inhibidores de histona desacetilasa; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad del grupo que consiste en enfermedad de huntington,
JPWO2008053913A1 (ja) 2006-11-02 2010-02-25 塩野義製薬株式会社 Ｍｍｐ−１３を選択的に阻害するスルホニルウレア誘導体
US20080153840A1 (en) 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
TW200836743A (en) 2007-01-29 2008-09-16 Xenon Pharmaceuticals Inc Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
EP2131657A1 (de) 2007-02-28 2009-12-16 Merck & Co., Inc. Substituierte benzodiazepinone, benzoxazepinone und benzothiazepinone als natriumkanalblocker
JP5497429B2 (ja) 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
EP2139480A1 (de) 2007-04-12 2010-01-06 CV Therapeutics Inc. Ranolazin für erhöhte insulinsekretion
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144483A2 (en) * 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2009026444A1 (en) 2007-08-22 2009-02-26 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
EA201000316A1 (ru) 2007-09-12 2010-10-29 ВАЙЕТ ЭлЭлСи Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2709186A1 (en) 2007-12-19 2009-06-25 Wyeth Llc 4-imidazolidinones as kv1.5 potassium channel inhibitors
PL2231662T3 (pl) 2007-12-19 2011-11-30 Genentech Inc 8-anilinoimidazopirydyny oraz ich zastosowanie jako czynników przeciwnowotworowych i/lub przeciwzapalnych
WO2009079630A1 (en) 2007-12-19 2009-06-25 Wyeth 4-imidazolidinones as kv1.5 potassium channel inhibitors
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
WO2009089027A1 (en) 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Phosphodiesterase inhibitors
WO2009100380A1 (en) 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
CN101910169A (zh) 2008-02-13 2010-12-08 卫材R&D管理有限公司 双环胺衍生物
JP2009286773A (ja) 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
US20110288070A1 (en) 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2009137499A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
DE102008024182A1 (de) 2008-05-19 2009-11-26 Merck Patent Gmbh Verbindungen für organische elektronische Vorrichtung
CA2725573A1 (en) 2008-06-06 2009-12-10 Abbott Laboratories Novel 1,2,4 oxadiazole compounds and methods of use thereof
BRPI0914927B8 (pt) 2008-06-17 2021-05-25 Astrazeneca Ab composto, composição farmacêutica e uso de um composto
EP2307027A4 (de) 2008-07-11 2012-08-15 Neumedics Tetracyclinderivate mit reduzierter antibiotischer aktivität und neuroprotektiven eigenschaften
MY147281A (en) 2008-07-31 2012-11-30 Invenpro M Sdn Bhd An apparatus for washing a workpiece
US20110127309A1 (en) 2008-07-31 2011-06-02 Poh Huay Chua Pet carrier
KR101315628B1 (ko) 2008-08-12 2013-10-08 닛뽕소다 가부시키가이샤 함질소 헤테로고리 유도체 및 농원예용 살균제
CN102186812A (zh) 2008-08-18 2011-09-14 宇部兴产株式会社 制备氟烷基芳基亚磺酰基化合物及其氟化的化合物的方法
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
JP2012502047A (ja) 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法
WO2010053757A1 (en) * 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US8389500B2 (en) 2008-10-30 2013-03-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
WO2010056865A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
WO2010068461A1 (en) 2008-11-25 2010-06-17 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
BRPI0922937A2 (pt) 2008-12-05 2019-09-24 Hoffmann La Roche inibidores de pirrolopirazinil uréia quinase
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
CN102307871A (zh) 2008-12-08 2012-01-04 西特里斯药业公司 作为沉默调节蛋白调节剂的异吲哚啉酮和相关的类似物
JP5271069B2 (ja) 2008-12-24 2013-08-21 三和シヤッター工業株式会社 開閉装置
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
BRPI1012282A2 (pt) 2009-03-27 2015-09-22 Presidio Pharmaceuticals Inc inibidores de anel fundidos da hepatite c.
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
AU2010276537B2 (en) 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
KR101428346B1 (ko) * 2009-09-28 2014-08-07 에프. 호프만-라 로슈 아게 벤즈옥사제핀 ｐｉ3ｋ 억제 화합물 및 사용 방법
WO2011042920A1 (en) 2009-10-07 2011-04-14 Decode Genetics Ehf Genetic variants indicative of vascular conditions
WO2011056985A2 (en) * 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US8323911B2 (en) 2010-05-13 2012-12-04 University Of South Carolina High throughput assay for discovering new inhibitors of the GIRK1/4 channel
EP2588197B1 (de) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Kondensierte heterozyklische verbindungen als ionenkanalmodulatoren
WO2012019071A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating sarcopenia
WO2012019076A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012037105A1 (en) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
WO2012036233A1 (ja) 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
DK2619212T3 (en) 2010-09-21 2016-03-21 Purdue Pharma Lp BUPRENORPHINANALOGER AS opioid receptor agonists and / or antagonists
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
WO2012071509A2 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
AR084019A1 (es) 2010-11-30 2013-04-17 Astrazeneca Ab DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh
JP5675428B2 (ja) 2011-02-25 2015-02-25 サンドビック株式会社 ベルトプレス装置
BR112013024122A2 (pt) * 2011-03-21 2019-09-24 Hoffmann La Roche compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
GB2507884B (en) 2011-06-03 2019-10-23 Signpath Pharma Inc Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
NO3175985T3 (de) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
KR20140036269A (ko) 2011-07-01 2014-03-25 바이엘 인텔렉쳐 프로퍼티 게엠베하 Alk1 억제제로서의 히드록시메틸아릴-치환된 피롤로트리아진
US20140221286A1 (en) 2011-09-21 2014-08-07 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013112932A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
ES2805341T3 (es) 2012-06-13 2021-02-11 Acesion Pharma Aps Composiciones farmacéuticas para terapia de combinación
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
CA2881544A1 (en) 2014-02-13 2015-08-13 Anna Chiu Solid forms of a late sodium current inhibitor
CN104844535A (zh) 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法

Also Published As

Publication number Publication date
MX2013014843A (es) 2014-03-31
MA35808B1 (fr) 2014-12-01
US20150239904A1 (en) 2015-08-27
TWI466873B (zh) 2015-01-01
SI2966067T1 (en) 2018-02-28
ES2657169T3 (es) 2018-03-01
PT2966067T (pt) 2018-01-30
SI2726469T1 (sl) 2015-10-30
EP2726469B1 (de) 2015-08-12
KR101919634B1 (ko) 2018-11-16
EA025095B1 (ru) 2016-11-30
CN103635467B (zh) 2017-08-04
PL2966067T3 (pl) 2018-04-30
US9695192B2 (en) 2017-07-04
PT2726469E (pt) 2015-10-27
EA031189B1 (ru) 2018-11-30
IL229714A0 (en) 2014-01-30
JP6470969B2 (ja) 2019-02-13
AU2012279214A1 (en) 2013-05-02
TW201313692A (zh) 2013-04-01
EP2966067A1 (de) 2016-01-13
BR112013032027A2 (pt) 2016-09-06
AR086829A1 (es) 2014-01-22
EA201690899A1 (ru) 2016-12-30
US8962610B2 (en) 2015-02-24
IL229714B (en) 2018-04-30
US20130005706A1 (en) 2013-01-03
ES2549654T3 (es) 2015-10-30
CN107325111A (zh) 2017-11-07
JP2018203771A (ja) 2018-12-27
EA201391628A1 (ru) 2014-06-30
MX338916B (es) 2016-05-03
HK1219098A1 (zh) 2017-03-24
JP2014518277A (ja) 2014-07-28
NZ618684A (en) 2016-02-26
JP2017088630A (ja) 2017-05-25
EP2726469A1 (de) 2014-05-07
PL2726469T3 (pl) 2016-01-29
KR20140045394A (ko) 2014-04-16
AU2012279214B2 (en) 2015-07-30
WO2013006463A1 (en) 2013-01-10
EP2966067B1 (de) 2017-10-25
HK1197061A1 (en) 2015-01-02
CN103635467A (zh) 2014-03-12
CA2838234A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
BR112013031251A2 (de)
BR112013027245A2 (de)
BR112013027830A2 (de)
BR112013028733A2 (de)
BR112013027121A2 (de)
BR112013027452A2 (de)
BR112013031556A2 (de)
NO3175985T3 (de)
BR112013032380A2 (de)
BR112013032377A2 (de)
BR112013032368A2 (de)
BR112013027761A2 (de)
BR112013027836A2 (de)
BR112013032392A2 (de)
BR112013027871A2 (de)
BR112013032394A2 (de)
BR112013030734A2 (de)
BR112013027657A2 (de)
BR112013027112A2 (de)
BR112013033177A2 (de)
BR112013027874A2 (de)
BR112013027764A2 (de)
CN302202672S (zh) 非公路自卸车驾驶室（2）
CN301884589S (zh) 上衣（28）
CN301585169S (zh) 布（1100243）